Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QLT licenses Atrigel for up to $30 million

This article was originally published in Scrip

Executive Summary

QLT has licensed the rights to its Atrigel sustained-release drug technology to Reckitt Benckiser Pharmaceuticals for up to $30 million. QLT USA, the trademark holder of Atrigel, has signed an exclusive licence agreement with Reckitt for the development of the technology, except for certain rights being retained by QLT USA and its prior licensees. QLT USA has received an aggregate up-front payment of $25 million and could receive potential payments of up to $5 million based on the successful development of two Atrigel-formulated products. Reckitt acquired 18 employees from QLT USA and will take over its corporate facility in Fort Collins, Colorado. Bob Butchofsky, QLT president and CEO, said the deal would bring the company's total proceeds from its announced non-core asset transactions to around $240 million. QLT plans to sell a remaining non-core asset, Eligard, a leuprolide acetate for injectable suspension for the palliative treatment of advanced prostate cancer, soon. Eligard is a registered trademark of Sanofi-Aventis.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts